ARRY-502 / Pfizer - LARVOL DELTA

Array BioPharma provides clinical update on ARRY-502 for asthma at Scientific Meeting (Array Biopharma Press Release) - P2, N=184; NCT01561690; Sponsor: Array BioPharma; "ARRY-502 met the primary endpoint in the trial, showing improved pre-bronchodilator Forced Expiratory Volume in one second (FEV1), a measure of lung function, by 3.9% versus placebo, achieving statistical significance (p=0.02).  FEV1 responses for the total cohort were statistically significant on a week by week basis. "

P2 data • Asthma